Allosteric LFA-1 inhibitors modulate natural killer cell function

Molecular Pharmacology

Volumn 75, Issue 2, 2009, Pages 355-362

  Weitz Schmidt, Gabriele ^a   Chreng, Stéphanie ^a   Riek, Simone ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; IMMUNOMODULATING AGENT; LFA 878; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 INHIBITOR; MEVINOLIN; UNCLASSIFIED DRUG; XVA 143;

ALLOSTERISM; ARTICLE; CELL STRAIN K 562; CELL VIABILITY; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOMODULATION; LEUKOCYTE ADHERENCE; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; PRIORITY JOURNAL;

BIOPHYSICAL PROCESSES; CELL ADHESION; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; SIGNAL TRANSDUCTION;

EID: 59449097822     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.051169     Document Type: Article

References (40)

1. Barber DF, Faure M, and Long EO (2004) LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 173:3653-3659.
2. Becknell B and Caligiuri MA (2005) Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86:209-239.
3. Borel JF and Kis ZL (1991) The discovery and development of cyclosporine (Sandimmune). Transplant Proc 23:1867-1874.
4. Bryceson YT, March ME, Ljunggren HG, and Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214:73-91.
5. Clausen J, Vergeiner B, Enk M, Petzer AL, Gastl G, and Gunsilius E (2003) Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology 207:85-93.
6. Cutts JL, Scallen TJ, Watson J, and Bankhurst AD (1989) Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 139:550-557.
7. Endo A (2008) A gift from nature: the birth of the statins. Nat Med 14:1050-1052.
8. Fildes JE, Yonan N, and Leonard CT (2008) Natural killer cells and lung transplantation, roles in rejection, infection, and tolerance. Transplant Immunol 19:1-11.
9. Graf B, Bushnell T, and Miller J (2007) LFA-1-mediated T cell costimulation through increased localization of TCR/class II complexes to the central supramolecular activation cluster and exclusion of CD45 from the immunological synapse. J Immunol 179:1616-1624.
10. Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715-2729.
11. Hanna J and Mandelboim O (2007) When killers become helpers. Trends Immunol 28:201-206.
12. Introna M, Allavena P, Spreafico F, and Mantovani A (1981) Inhibition of human natural killer activity by cyclosporin A. Transplantation 31:113-116.
13. Johann S, Blümel G, Lipp M, and Förster R (1995) A versatile flow cytometry-based assay for the determination of short- and long-term natural killer cell activity. J Immunol Methods 185:209 -216.
14. Johansson S, Berg L, Hall H, and Höglund P (2005) NK cells: elusive players in autoimmunity. Trends Immunol 26:613-618.
15. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, Cottens S, Weitz-Schmidt G, and Hommel U (1999) Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 292:1-9.
16. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, and Gottlieb AB (2008) Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 158:1107-1116.
17. Linnebacher M, Blauscha C, Wacke R, Kottek T, Stein S, Kiefel V, Hakenberg OW, and Klar E (2008) An in vitro system for the determination of individualized immunosuppression. Transplant Proc 40:918-920.
18. Maki G, Klingemann HG, Martinson JA, and Tam YK (2001) Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res 10:369 -383.
19. Muldoon MF, Flory JD, Marsland A, Manuck SB, Whiteside TL, and Rabin B (1997) Effects of lovastatin on the immune system. Am J Cardiol 80:1391-1394.
20. Osman MS, Burshtyn DN, and Kane KP (2007) Activating Ly-49 receptors regulate
21. LFA-1-mediated adhesion by NK cells. J Immunol 178:1261-1267.
22. Perez OD, Mitchell D, Jager GC, and Nolan GP (2004) LFA-1 signaling through
23. + natural killer cells. Blood 104:1083-1093.
24. Piriou L, Chilmonczyk S, Genetet N, and Albina E (2000) Design of a flow cytometric
25. assay for the determination ofnatural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 41:289-297.
26. Pores-Fernando AT, Gaur S, Doyon Y, and Zweifach A (2008) Calcineurin-dependent lytic granule exocytosis in NK-92 natural killer cells. Cell Immunol. doi: 10.1016/ j.cellimm.2008.07.004.
27. Rocha PN, Plumb TJ, Crowley SD, and Coffman TM (2003) Effector mechanisms in transplant rejection. Immunol Rev 196:51-64.
28. Schmits R, Kündig TM, Baker DM, Shumaker G, Simard JJ, Duncan G, Wakeham A, Shahinian A, van der Heiden A, Bachmann MF, et al. (1996) LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J Exp Med 183:1415-1426.
29. Sedrani R, Cottens S, Kallen J, and Schuler W (1998) Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 30:2192-2194.
30. Shimaoka M, Salas A, Yang W, Weitz-Schmidt G, and Springer TA (2003) Small molecule integrin antagonists that bind to the beta 2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 19:391-402.
31. Shimaoka M and Springer TA (2004) Therapeutic antagonists and the conformational regulation of the beta 2 integrins. Curr Top Med Chem 4:1485-1495.
32. Tanaka T, Porter CM, Horvath-Arcidiacono JA, and Bloom ET (2007) Lipophilic statins suppress cytotoxicity by freshly isolated natural killer cells through modulation of granule exocytosis. Int Immunol 19:163-173.
33. Vampa ML, Norman PJ, Burnapp L, Vaughan RW, Sacks SH, and Wong W (2003) Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch. Transplantation 76:1220-1228.
34. Vivier E, Tomasello E, Baratin M, Walzer T, and Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503-510.
35. Wai LE, Fujiki M, Takeda S, Martinez OM, and Krams SM (2008) Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 85:145-149.
36. + natural killer cell subpopulations. Blood 110: 1530-1539.
37. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, and Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692.
38. Weitz-Schmidt G, Welzenbach K, Dawson J, and Kallen J (2004) Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J Biol Chem 279:46764-46771.
39. Welzenbach K, Hommel U, and Weitz-Schmidt G (2002) Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. Molecular insights into integrin inhibition. J Biol Chem 277:10590 -10598.
40. Young NT (2004) Immunobiology of natural killer lymphocytes in transplantation. Transplantation 78:1-6.